Mucopolysaccharidosis II (Hunter Syndrome): Market View

This reports provides a data-driven overview of the current and future competitive landscape in Mucopolysaccharidosis II (Hunter Syndrome) Therapeutics.

In 2024 and 2029, India is anticipated to have the highest number of diagnosed prevalent cases of MPS II, representing a large portion of global cases.

Currently, the MPS II market has only three FDA-approved innovator drugs available to treat MPS II.

The MPS II pipeline holds 15 molecules, with only two assets in the pre-registration stage, three assets in Phase III development, and two assets in Phase II development.

Over the past decade, 36 clinical trials have been conducted in MPS II. The highest number of studies was initiated in 2015, 2017, and 2023, with five trials each.

Over the past decade, acquisitions in North America represented a major share of transactions.

Scope

GlobalData's Mucopolysaccharidosis II (Hunter Syndrome): Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Mucopolysaccharidosis II (Hunter Syndrome) Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Mucopolysaccharidosis II (Hunter Syndrome) Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.